7 results
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
The primary objective of this trial is to describe the safety and tolerability of prolonged exposure to cebranopadol in subjects suffering from cancer related pain
The aim of this study is to (i) determine non-invasive visualisation of tumour hypoxia with [18F] HX4 PET imaging in cervix carcinomas; (ii) correlate [18F] HX4 PET images with blood and tissue markers for hypoxia; (iii) investigate the quality and…
Primary Objective: Visualization and quantification of tumor hypoxia with [18F] HX4 PET imagingSecondary Objectives: - Correlation of [18F] HX4 with local tumor recurrence and survival- Correlation of hypoxia imaging with blood hypoxia markers -…
Primary • To evaluate the effects of cebranopadol and oxycodone on respiratory drive.Secondary• To evaluate the pupil response/ pupillometry following single oral doses of cebranopadol and oxycodone• To evaluate the effects of single oral doses of…
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…
Objectives - Core StudyPrimary Objectives• To evaluate the effects of oral ALZ-801 in subjects with Early AD who have the APOE4/4 or APOE3/4 genotype, on the plasma biomarkers of core AD pathology and brain volumes* Primary Plasma Biomarker Outcome…